Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...

Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA ...

Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) ...

Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., ...

Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and ...

Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.

Across the recent three months, 5 analysts have shared their insights on Regenxbio RGNX, expressing a variety of opinions ...

Dr. Andrew Lam – doctor, surgeon, author and storyteller extraordinaire – spoke to students at Springfield High School Nov. 1 ...